Trade Mark Journal No.2025/042 17 October 2025
WO0000001879299 (5,44)
Office of origin: United States of America
Date of International Registration:21 April 2025
Date of designation in the UK:
21 April 2025
The mark consists of two interlocking triquetra or arc symbols where one of the overlapping shapes is partially open on the right side.
International priority date claimed: 21 October 2024
(United States of America)
(98811671)
- Class 5
- Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders.
- Class 44
- Medical services; medical information services; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders; medical consulting services in the field of genetic diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of genetic diseases and disorders, via an online database that collects data and information on genetic diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of genetic diseases and disorders; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; medical consulting services in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, via an online database that collects data and information on cardiovascular, metabolic, neurological and inflammatory diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of cardiovascular, metabolic, neurological and inflammatory diseases and disorders.
Ionis Pharmaceuticals, Inc.
Representative: Brian J. Focarino Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, IP Docketing Department, Washington DC 20004, UNITED STATES OF AMERICA